PolyPid (NASDAQ:PYPD) Trading Up 4.8%

PolyPid Ltd. (NASDAQ:PYPD – Get Rating) was up 4.8% during trading on Wednesday . The company traded as high as $0.39 and last traded at $0.37. Approximately 94,833 shares traded hands during mid-day trading, a decline of 67% from the average daily volume of 288,958 shares. The stock had previously closed at $0.35.

PolyPid Stock Down 7.0 %

The business has a fifty day moving average of $0.42 and a 200 day moving average of $0.64. The firm has a market cap of $6.84 million, a P/E ratio of -0.22 and a beta of 1.25. The company has a quick ratio of 2.75, a current ratio of 2.75 and a debt-to-equity ratio of 0.59.

PolyPid (NASDAQ:PYPD – Get Rating) last announced its quarterly earnings results on Wednesday, May 10th. The company reported ($0.28) earnings per share (EPS) for the quarter. On average, equities research analysts predict that PolyPid Ltd. will post -1.05 EPS for the current year.

Institutional Investors Weigh In On PolyPid

Several large investors have recently modified their holdings of the business. Boothbay Fund Management LLC boosted its position in PolyPid by 514.5% during the first quarter. Boothbay Fund Management LLC now owns 122,898 shares of the company’s stock valued at $57,000 after purchasing an additional 102,898 shares during the last quarter. UBS Group AG boosted its position in PolyPid by 29.9% during the first quarter. UBS Group AG now owns 285,399 shares of the company’s stock valued at $1,558,000 after purchasing an additional 65,746 shares during the last quarter. Silverarc Capital Management LLC lifted its position in shares of PolyPid by 1.2% in the first quarter. Silverarc Capital Management LLC now owns 218,175 shares of the company’s stock valued at $1,191,000 after buying an additional 2,555 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of PolyPid in the first quarter valued at approximately $72,000. Finally, Raymond James Financial Services Advisors Inc. lifted its position in shares of PolyPid by 83.3% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 52,251 shares of the company’s stock valued at $285,000 after buying an additional 23,752 shares during the last quarter. 2.48% of the stock is currently owned by institutional investors.

PolyPid Company Profile

(Get Rating)

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs.